Comprehensive review confirms that the Oncotype DX Breast Recurrence Score ® test accurately predicts breast cancer outcomes and chemotherapy benefit for patients regardless of race or ethnicity ...

New ASCO Recommendations Increase Proportion of Women Who Can Be Spared Chemotherapy Based on Landmark TAILORx and NSABP B-20 Randomized Clinical Trials Additional Secondary Analysis of TAILORx Trial ...

MADISON, Wis., April 28, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leader in advanced cancer diagnostics, today announced that recommended use of its Oncotype DX Breast Recurrence ...

REDWOOD CITY, Calif., March 25, 2019 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that new data presented at the 16th St. Gallen International Breast Cancer Conference in Vienna ...

The Oncotype DX Breast Recurrence Score® test, which has been used by over 1.5 million patients, indicates the likelihood of your cancer recurring based on the biology of your tumor. 1,2,3,4 It is ...

Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced that the UK’s National Institute for Health and Care Excellence (NICE) has recommended the expanded use of ...

- Updated RxPONDER study analysis provides further evidence that the test identifies the majority of women with early-stage, node-positive breast cancer who can avoid chemotherapy MADISON, Wis., Dec.

Based on results presented at the ongoing San Antonio Breast Cancer Symposium, the gene panel was found to predict the risk of disease recurrence in women who had undergone breast conservation surgery ...

Genomic Health (GHDX), an oncology based biotech company, recently presented results from seven new studies for its flagship product, Oncotype DX breast cancer test. Data presented at a recently held ...

At first glance, given that the two assays share only one overlapping gene, it would appear that the two assays have little in common in terms of genomic content. However, the priority gene lists are ...

Pertuzumab/Docetaxel/Carboplatin/Trastuzumab Regimen in Human Epidermal Growth Factor Receptor 2–Positive Early, Locally Advanced, and Oligometastatic Breast Cancer ...